Use of ghostwriters, guest authors appears frequent for studies involving rofecoxib

An examination of medical articles about rofecoxib (a nonsteroidal anti-inflammatory drug) and court documents from litigation related to this product indicates that company employees or other unacknowledged authors were frequently involved in writing clinical trial articles and review articles, but that primary authorship was often attributed to academically affiliated investigators who may have had little to do with the study, or who did not always disclose financial support from the sponsor of the study, according to an article in the April 16 issue of JAMA.

Authorship in biomedical publication provides recognition while establishing accountability and responsibility. Guest authorship has been defined as the designation of an individual who does not meet authorship criteria, according to background information in the article. Ghostwriting has been defined as the failure to designate an individual (as an author) who has made a substantial contribution to the research or writing of a manuscript.

“Recent litigation related to rofecoxib provided a unique opportunity to examine guest authorship and ghostwriting, practices that have been suspected in biomedical publication but for which there is little documentation,” the authors write.

Joseph S. Ross, M.D., M.H.S., of Mount Sinai School of Medicine, New York, and colleagues conducted a case-study review of court documents, in combination with a review of the relevant medical literature, to describe the practice of guest authorship and ghostwriting related to rofecoxib. The researchers used court documents, created predominantly between 1996 and 2004, originally obtained during litigation related to rofecoxib against Merck & Co. Inc. In addition, publicly available articles related to rofecoxib were identified via MEDLINE. Approximately 250 documents were relevant for the review.

When publishing their own clinical trials (designed, conducted, and sponsored by Merck), documents were found describing Merck scientists often working to prepare manuscripts and subsequently recruiting external, academically affiliated investigators to collaborate on the manuscript as guest authors. “Recruited authors were frequently placed in the first and second positions of the authorship list. For the publication of scientific review papers, documents were found describing Merck marketing employees developing plans for manuscripts, contracting with medical publishing companies to ghostwrite manuscripts, and recruiting external, academically affiliated investigators to be authors,” the researchers write. Documents indicated that medical publishing companies provided near complete drafts of review manuscripts to authors for editing, in addition to managing submissions and revisions.

Documents were also found describing Merck compensating investigators with honorarium for agreeing to serve as authors on review manuscripts ghostwritten on their behalf by medical publishing companies. “Among 96 relevant published articles, we found that 92 percent (22 of 24) of clinical trial articles published a disclosure of Merck’s financial support, but only 50 percent (36 of 72) of review articles published either a disclosure of Merck sponsorship or a disclosure of whether the author had received any financial compensation from the company.”

“This case-study review of industry documents related to rofecoxib demonstrates that Merck used a systematic strategy to facilitate the publication of guest authored and ghost written medical literature,” the authors write. “We are hopeful that our findings encourage discussion of ways in which to improve the integrity of research. The medical profession and the pharmaceutical industry should agree that collaborations must be conducted with the highest standards. We suggest that academic researchers consistently provide to the journals the author contributions for all manuscripts, including original research, meta-analyses, reviews, and commentaries, and disclose relationships and support from all industry sources, regardless of the journal’s requirements.”

“Authors who ‘sign-off’ on or ‘edit’ original manuscripts or reviews written explicitly by pharmaceutical industry employees or by medical publishing companies should offer full authorship disclosure, such as, ‘drafting of the manuscript was done by representatives from XYZ, Inc.; the authors were responsible for critical revisions of the manuscript for important intellectual content.’ A coordinated oversight strategy involving academic physicians, journal editors, and industry representatives is necessary to discourage both guest authorship and ghostwriting and improve the integrity of the biomedical authorship system,” the authors conclude.

Source: JAMA and Archives Journals

Related stories:

Editors' leadership role impacts on quality of biomedical research journals
The factors allowing a journal to achieve high quality are not fully understood, but good editorial practices such as accurate and author-helpful peer review and in-house editing are thought to be important. Now, a new study provides quantitative evidence that another aspect of good editorial practice – editors' expectations that articles adhere to international standards for quality reporting – is strongly related to journal quality. The research is published July 2 in the online, open-access journal PLoS ONE.
Review of online breast cancer information encourages healthy skepticism for consumers
In an extended analysis of Web pages dedicated to disseminating breast cancer information, researchers at two University of Texas institutions in the Houston have determined that while most breast cancer data found online was accurate, one in 20 breast cancer Web pages featured inaccuracies and sites displaying complementary and alternative medicine were 15 times more likely to contain false or misleading health information.
Bullying-suicide link explored in new study
Researchers at Yale School of Medicine have found signs of an apparent connection between bullying, being bullied and suicide in children, according to a new review of studies from 13 countries published in the International Journal of Adolescent Medicine and Health.
Breast self-exams do not appear to reduce breast cancer deaths
It is a staple of women's health advice and visits to the OB/GYN: the monthly breast self-exam to check for lumps or other changes that might signal breast cancer. However, a review of recent studies says there is no evidence that self-exams actually reduce breast cancer deaths.
Rx for time-crunched physicians
With their waiting rooms crowded and exam rooms full, many physicians say they are too busy to be good communicators. Those who study physician time-management think otherwise. Certain communication skills can foster efficiency and effectiveness during an office visit without sacrificing rapport with patients, according to researchers at the University of Washington (UW) and the University of Rochester.
Can microorganisms be a solution to the world's energy problems?
Microorganisms once reigned supreme on the Earth, thriving by filling every nook and cranny of the environment billions of years before humans first arrived on the scene. Now, this ability of microorganisms to grow from an almost infinite variety of food sources may play a significant role in bailing out society from its current energy crisis, according to the Biodesign Institute's Bruce Rittmann, Rosa Krajmalnik-Brown, and Rolf Halden.
Edit your DNA: 'Gene wiki' to debut on Wikipedia
(AP) -- Researchers plan to create a library of human genetics, with entries on the workings of individual genes, and make it available for anyone in Wikipedia rather than in an obscure academic format.
Members of consumer-driven health plans choosing less care
Consumer-driven health plans (CDHP) -- hailed since their inception in 2000 as a tool to help control costs -- are resulting in members forgoing care and discontinuing drugs to treat chronic medical problems, according to two newly published studies.

News discussion:

Medicine & Health news